uniQure to price its IPO of stock between $13.00 and $15.00 per share

Jefferies and Leerink Swann are the bookrunners; Piper Jaffray assists

By Devika Patel

Knoxville, Tenn., Jan. 24 - uniQure BV will sell 4.6 million ordinary shares in its initial public offering with a 30-day greenshoe of 690,000 additional shares, according to a Form F-1/A filed Friday with the Securities and Exchange Commission. The deal was announced Jan. 2.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

Jefferies and Leerink Swann are the joint bookrunning managers. Piper Jaffray & Co. is the co-manager.

Proceeds will be used to build and equip the company's manufacturing facility in Lexington, Mass., and for clinical development of Glybera and other products, clinical trials, working capital and general corporate purposes, including debt repayment and potential acquisitions.

The Amsterdam company develops gene therapy products. The company intends to list its common stock on the Nasdaq stock exchange under the symbol "QURE."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.